Search Results - Joan Cox Gill

Refine Results
  1. 1
    Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project

    Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project by Marilyn Johnson, J. Michael Soucie, Joan Cox Gill

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    High‐dose DDAVP intranasal spray (Stimate<sup>®</sup>) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A

    High‐dose DDAVP intranasal spray (Stimate<sup>®</sup>) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand dise... by Cindy Leissinger, David L. Becton, Charles J. Cornell, Joan Cox Gill

    Published 2001
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets

    Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets by Brian Boylan, Cunji Gao, Vipul Rathore, Joan Cox Gill, Debra K. Newman, Peter J. Newman

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage

    Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage by Paula M. Jacobi, Joan Cox Gill, Veronica H. Flood, David Jakab, Kenneth D. Friedman, Sandra L. Haberichter

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function

    Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function by Veronica H. Flood, Kenneth D. Friedman, Joan Cox Gill, Patricia A. Morateck, J.S. WREN, John P. Scott, Robert R. Montgomery

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain

    Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain by Cunji Gao, Brian Boylan, Dan Bougie, Joan Cox Gill, Jessica Birenbaum, Debra K. Newman, Richard H. Aster, Peter J. Newman

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

    Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network by Thomas C. Abshire, Joan Cox-Gill, Christine L. Kempton, Frank W.G. Leebeek, Manuel Carção, Peter A. Kouides, Sharyne Donfield, Erik Berntorp

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD

    Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD by Veronica H. Flood, Joan Cox Gill, Patricia A. Morateck, Pamela A. Christopherson, Kenneth D. Friedman, Sandra L. Haberichter, Raymond G. Hoffmann, Robert R. Montgomery

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease

    Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease by Veronica H. Flood, Joan Cox Gill, Kenneth D. Friedman, Pamela A. Christopherson, Paula M. Jacobi, Raymond G. Hoffmann, Robert R. Montgomery, Sandra L. Haberichter

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival

    Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival by Sandra L. Haberichter, Michael Balistreri, Pamela A. Christopherson, Patricia A. Morateck, Stefana Gavazova, Daniel B. Bellissimo, Marilyn J. Manco‐Johnson, Joan Cox Gill, Robert R. Montgomery

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Type 2M von Willebrand Disease: F606I and I662F Mutations in the Glycoprotein Ib Binding Domain Selectively Impair Ristocetin- but not Botrocetin-Mediated Binding of von Willebrand Factor to Platelets

    Type 2M von Willebrand Disease: F606I and I662F Mutations in the Glycoprotein Ib Binding Domain Selectively Impair Ristocetin- but not Botrocetin-Mediated Binding of von Willebrand... by Cheryl A. Hillery, David J. Mancuso, J. Evan Sadler, Jay W. Ponder, Mary A. Jozwiak, Pamela A. Christopherson, Joan Cox Gill, James G. Scott, Robert R. Montgomery

    Published 1998
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Thrombolysis in Pediatric Stroke Study

    Thrombolysis in Pediatric Stroke Study by Michael Rivkin, Gabrielle deVeber, Rebecca Ichord, Adam Kirton, Anthony K.C. Chan, Collin A. Hovinga, Joan Cox Gill, Anikó Szabó, Michael D. Hill, Kelley Scholz, Catherine Amlie‐Lefond

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

    Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease by Joan Cox Gill, Giancarlo Castaman, Jerzy Windyga, Peter A. Kouides, Margaret V. Ragni, Frank W.G. Leebeek, Ortrun Obermann-Slupetzky, Miranda Chapman, Sandor Fritsch, Borislava G. Pavlova, Isabella Presch, Bruce M. Ewenstein

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Crucial role for the VWF A1 domain in binding to type IV collagen

    Crucial role for the VWF A1 domain in binding to type IV collagen by Veronica H. Flood, Abraham Schlauderaff, Sandra L. Haberichter, Tricia L. Slobodianuk, Paula M. Jacobi, Daniel B. Bellissimo, Pamela A. Christopherson, Kenneth D. Friedman, Joan Cox Gill, Raymond G. Hoffmann, Robert R. Montgomery

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)

    Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) by Thomas C. Abshire, Augusto B. Federici, M. T. Alvárez, Joel Bowen, Manuel Carção, Joan Cox Gill, Nigel S. Key, Peter A. Kouides, Karin Kurnik, Alice Lail, Frank W.G. Leebeek, Michael Makris, P.M. Mannucci, Rochelle Winikoff, E. Berntorp

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population

    VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population by Daniel B. Bellissimo, Pamela A. Christopherson, Veronica H. Flood, Joan Cox Gill, Kenneth D. Friedman, Sandra L. Haberichter, Amy D. Shapiro, Thomas C. Abshire, Cindy Leissinger, W. Keith Hoots, Jeanne M. Lusher, Margaret V. Ragni, Robert R. Montgomery

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres

    Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres by Vanessa R. Byams, Peter A. Kouides, R. KULKARNI, Judith Baker, Deborah Brown, Joan Cox Gill, Althea M. Grant, Allison James, Barbara A. Konkle, Jennifer Maahs, M Dumas, S. McALISTER, Danielle Nance, Diane J. Nugent, Claire S. Philipp, J. Michael Soucie, Ellen Stang

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System

    Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System by Roshni Kulkarni, Rodney Presley, Jeanne M. Lusher, Amy D. Shapiro, Joan Cox Gill, M. Manco‐Johnson, Marion A. Koerper, Thomas C. Abshire, Donna DiMichele, W. Keith Hoots, Prasad Mathew, Diane J. Nugent, S. Geraghty, Bruce L. Evatt, J. Michael Soucie

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial by Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar, Edward H. Romond, Amy D. Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, T. T. Yee, Robert Klamroth, Wing-Yen Wong, Miranda Chapman, Werner Engl, Peter L. Turecek, Tobias M. Suiter, Bruce M. Ewenstein

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Comparative pharmacokinetics of <scp>rVIII</scp>‐SingleChain and octocog alfa (Advate<sup>®</sup>) in patients with severe haemophilia A

    Comparative pharmacokinetics of <scp>rVIII</scp>‐SingleChain and octocog alfa (Advate<sup>®</sup>) in patients with severe haemophilia A by Robert Klamroth, Mindy L. Simpson, M. von Depka‐Prondzinski, Joan Cox Gill, Massimo Morfini, Jerry S. Powell, Elena Santagostino, Joanna A. Davis, Angela Huth‐Kühne, Cindy Leissinger, Peter Neumeister, Debra M. Bensen-Kennedy, Annette Feussner, Tharin Limsakun, Meijian Zhou, Alex Veldman, Katie St. Ledger, Nicole Blackman, Ingrid Pabinger

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: